On March 11, 2020, IDEAYA Biosciences, Inc. (the "Company") entered into a Clinical Trial Collaboration and Supply Agreement (the "Agreement") with Pfizer Inc. ("Pfizer"), pursuant to which the Company and Pfizer will collaborate on a portion of the Company’s Phase 1/2 study in Metastatic Uveal Melanoma (MUM) and other solid tumors harboring activating GNAQ or GNA11 hotspot mutations, in each case pertaining to the clinical evaluation of the Company’s IDE196 compound in combination with Pfizer’s MEK inhibitor, binimetinib (the "Combination Study") (Filing, 8-K, Ideaya Biosciences, MAR 11, 2020, View Source [SID1234555643]). Pursuant to the Agreement, the Company is the sponsor of the Combination Study and the Company will provide the Company’s IDE196 compound and will pay for the costs of the Combination Study. Pfizer will provide binimetinib for the Combination Study at no cost to the Company. The Company and Pfizer will jointly own clinical data from the Combination Study and all inventions relating to the combined use of IDE196 and binimetinib. The Company and Pfizer will form a joint development committee responsible for coordinating all regulatory and other activities under the Agreement.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!